InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,426.40
(
0.12%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.84
(
0.06%
)
Bitcoin
65,306.50
(
0.26%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Bio_pete

Send PM Follow Ignore
Followers 17
Posts 1580
Boards Moderated 0
Alias Born 02/07/2007

Bio_pete

Re: tony111 post# 139604

Monday, 04/02/2012 1:56:53 PM

Monday, April 02, 2012 1:56:53 PM

Post# of 252254
KERX, they have enough cash to take the company into mid-2013. Adam Feurstein's article kind of put a damper on things. He fails to mention the possibility for decreased usage of Epo agents for those on Zerenex in his analysis. If the Phase III trial shows a reduced cost to maintain hemoglobin levels then it would be winner no matter the threat from generics.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up